mTOR Pathway and Molecularly Targeted Therapy

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

mTOR Pathway and Molecularly Targeted Therapy

The new pathologic classification of lung cancer affects clinical practice and opens new avenues for research, and new molecularly targeted strategies are being evaluated based on the new classification. The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is one of most commonly deregulated pathways in cancer. mTOR has a complex function and is tumor specific which necessitates the use of different classes of biomarkers to accurately predict responses to mTOR inhibitors. The mTOR inhibitors might only benefit patients with specific molecular alterations, therefore, predictive biomarkers are essential for future clinical trials to select the proper patients and adjust the dosage together with other targeted molecular therapy.

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger